EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Discovering a Novel AAV2-Based Capsid for RPE Transduction Via Intravitreal Injection for Leber Congenital Amaurosis Type 2 Gene Therapy

Sonali Singh, Meike Visel, Leah C Byrne, Zachary Engfer, Tyler Houston, Beth Wade, Paripoorna Sharma, Guillaume Luxardi, Krzysztof Palczewski, Ala Moshiri, John Flannery

Investigative Ophthalmology & Visual Science · 2026-11-12 · 67 (13) · 22

DOI: 10.1167/iovs.67.13.22 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, published on 2026-11-12. Written by Sonali Singh and 10 co-authors. Institution: Herbert Wertheim School of Optometry and Vision Science, University of California, Berkeley, California, United States. Major MEDLINE topics: Leber Congenital Amaurosis, Retinal Pigment Epithelium, Genetic Therapy, Dependovirus. 54 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose

Several retinal degenerations initiate because of gene defects in the outermost retinal layer, the retinal pigment epithelium (RPE). Subretinal injection achieves optimal RPE transduction but has limitations, including iatrogenic damage. Here, we develop and evaluate the efficacy of a novel adeno-associated virus (AAV) capsid with intravitreal delivery, in an effort to overcome limitations of subretinal delivery for treatment of retinal degenerations that require precise targeting of the outer retina.

Methods

We conducted a high-throughput screening of 1.28 × 109 AAV2 capsids, each with a different 7-mer peptide insertion to alter its binding properties, to be delivered with intravitreal (IVT) injection, a less invasive surgical procedure. A novel AAV variant, variant 3 (AAV2.Var3) was found to transduce RPE cells with CAG-GFP and Best1-GFP in mouse eyes. For comparison, a leading, clinical-stage vector that is also AAV2-based, 7m8, effectively transduces the outer retina but has limited success targeting RPE through IVT delivery. To test the therapeutic efficacy of variant 3, we packaged therapeutic gene, hRPE65, and injected it intravitreally in rd12 mice, a disease model for Leber congenital amaurosis type 2.

Results

AAV2.Var3-hRPE65 treated mice cohorts showed an increase in RPE65 protein expression and function as well as visual function in response to light flashes. Translatability of AAV2.Var3 for intravitreal gene delivery was validated by AAV2.Var3-Best1-GFP vector induced expression of GFP in peripheral RPE cells in non-human primate macaque.

Conclusions

Variant 3 is capable of RPE transduction with IVT injection, serving as a vehicle for less invasive IVT gene delivery to the RPE. Therapeutic gene delivery leads to functional results with efficiency limitations.

Subjects

MeSH terms (MEDLINE)

Leber Congenital AmaurosisRetinal Pigment EpitheliumGenetic TherapyDependovirusTransduction, GeneticParvovirinaeCapsidAnimalsIntravitreal InjectionsGenetic VectorsMiceGene Therapy AgentsDisease Models, AnimalMice, Inbred C57BLcis-trans-IsomerasesHumansGene Transfer TechniquesRetinoid Isomerohydrolase

Substances

cis-trans-IsomerasesRetinoid Isomerohydrolase

Authors and institutions

  • Herbert Wertheim School of Optometry and Vision Science, University of California, Berkeley, California, United States.
  • Helen Wills Neuroscience Institute, University of California, Berkeley, California, United States.
  • Department of Ophthalmology, University of Pittsburgh, Pennsylvania, United States.
  • Department of Neurobiology, University of Pittsburgh, Pennsylvania, United States.
  • Department of Bioengineering, University of Pittsburgh, Pennsylvania, United States.
  • Department of Physiology and Biophysics, University of California, Irvine, California, United States.

Cite

APA

Singh, S., Visel, M., Byrne, L. C., Engfer, Z., Houston, T., Wade, B., Sharma, P., Luxardi, G., Palczewski, K., Moshiri, A., & Flannery, J. (2026). Discovering a Novel AAV2-Based Capsid for RPE Transduction Via Intravitreal Injection for Leber Congenital Amaurosis Type 2 Gene Therapy. Investigative Ophthalmology & Visual Science, 67(13), 22. https://doi.org/10.1167/iovs.67.13.22

Vancouver

Singh S, Visel M, Byrne LC, Engfer Z, Houston T, Wade B, et al. Discovering a Novel AAV2-Based Capsid for RPE Transduction Via Intravitreal Injection for Leber Congenital Amaurosis Type 2 Gene Therapy. Investigative Ophthalmology & Visual Science. 2026;67(13):22. doi:10.1167/iovs.67.13.22

BibTeX
@article{Singh2026,
  author = {Singh, Sonali and Visel, Meike and Byrne, Leah C and Engfer, Zachary and Houston, Tyler and Wade, Beth and Sharma, Paripoorna and Luxardi, Guillaume and Palczewski, Krzysztof and Moshiri, Ala and Flannery, John},
  title = {Discovering a Novel AAV2-Based Capsid for RPE Transduction Via Intravitreal Injection for Leber Congenital Amaurosis Type 2 Gene Therapy},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  volume = {67},
  number = {13},
  pages = {22},
  doi = {10.1167/iovs.67.13.22}
}
Start for free →